Cardiovascular Risk Assessment Model for Diabetes Mortality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for cardiovascular risk assessment in diabetes patients rely heavily on traditional risk factors, which are insufficient in predicting mortality, as they fail to account for independent non-conventional biomarkers, leading to a high incidence of cardiovascular events despite effective control of conventional risk factors.
Innovation Solution
A method involving the determination of a set of biological parameters including gender, age, natriuretic peptide levels, renal function, diabetes duration, lipid metabolism, and calcium/phosphate metabolism, which are correlated to provide a risk score indicative of all-cause mortality, allowing for personalized medical treatment to reduce mortality risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional cardiovascular risk factors are used for risk assessment in diabetes patients, then the assessment method is simple and widely available, but the predictive accuracy for mortality is insufficient
Solution Approach 1:
The patent combines multiple independent biomarkers (natriuretic peptides, renin, Lp-PLA2, vitamin D3) with traditional risk factors into a unified risk assessment model. This merging of conventional and novel markers creates a comprehensive assessment tool that achieves high predictive accuracy (C-statistic >0.75) while maintaining clinical applicability through a standardized scoring system.
2Reliability
If multiple independent biomarkers are measured to improve risk prediction, then the discriminatory power increases, but the number of measurements and complexity increases
Solution Approach 1:
The patent segments the risk assessment into distinct, independently measurable biomarker components (natriuretic peptides for cardiac function, renin for renal function, Lp-PLA2 for inflammation, vitamin D3 for calcium metabolism). Each segment can be measured separately using established clinical assays, then integrated into the overall risk score. This segmentation maintains ease of operation while achieving high reliability.
3Reliability
If conventional risk factors are controlled effectively, then traditional treatment measures are successful, but cardiovascular events still occur at high incidence
Solution Approach 1:
The patent introduces novel biomarkers as intermediary indicators that reveal hidden risk mechanisms not captured by traditional factors. Natriuretic peptides serve as intermediaries for cardiac stress, renin for renal function, Lp-PLA2 for vascular inflammation, and vitamin D3 for metabolic regulation. These intermediaries provide lost information about independent risk pathways, enabling more accurate mortality prediction even when conventional risk factors are controlled.
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3E
AI summary
The present invention relates to methods for determining the risk of mortality in a patient with diabetes mellitus comprising the steps of analysing a set of biological parameters obtained from the patient, wherein the set of biological parameters comprises the patient's gender, the patient's age, at least one indicator of myocardial performance, an indicator of renal performance, the duration of diabetes mellitus in the patient defined in years, an indicator of lipid metabolism, and an indicator of blood calcium and/or phosphate metabolism, wherein the biological parameter are set into correlation, thereby providing a risk score, wherein the risk score is indicative for all-cause mortality of the patient within the next years, and wherein the risk score is indicative for a medical treatment of the patient to reduce the patient's risk of all-cause mortality.